196 related articles for article (PubMed ID: 9740703)
1. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
Rose PG; Blessing JA; Soper JT; Barter JF
Gynecol Oncol; 1998 Aug; 70(2):267-71. PubMed ID: 9740703
[TBL] [Abstract][Full Text] [Related]
2. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
3. Trimetrexate in the treatment of recurrent or advanced leiomyosarcoma of the uterus: a phase II study of the Gynecologic Oncology Group.
Smith HO; Blessing JA; Vaccarello L
Gynecol Oncol; 2002 Jan; 84(1):140-4. PubMed ID: 11748990
[TBL] [Abstract][Full Text] [Related]
4. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Sutton G; Blessing J; Hanjani P; Kramer P;
Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Lewandowski GS; Creasman WT; Webster KD
Gynecol Oncol; 1996 Oct; 63(1):101-4. PubMed ID: 8898177
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix.
Morris M; Brader KR; Burke TW; Levenback CF; Gershenson DM
Gynecol Oncol; 1998 Aug; 70(2):215-8. PubMed ID: 9740693
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of etoposide in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
Thigpen T; Blessing JA; Yordan E; Valea F; Vaccarello L
Gynecol Oncol; 1996 Oct; 63(1):120-2. PubMed ID: 8898180
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a gynecologic oncology group study.
Sutton G; Blessing JA; Ball H
Gynecol Oncol; 1999 Sep; 74(3):346-9. PubMed ID: 10479491
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Poplin EA; Liu PY; Delmore JE; Wilczynski S; Moore DF; Potkul RK; Fine BA; Hannigan EV; Alberts DS
Gynecol Oncol; 1999 Sep; 74(3):432-5. PubMed ID: 10479505
[TBL] [Abstract][Full Text] [Related]
10. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Rose PG; Blessing JA; Buller RE; Mannel RS; Webster KD
Gynecol Oncol; 2003 May; 89(2):267-70. PubMed ID: 12713990
[TBL] [Abstract][Full Text] [Related]
11. Salvage chemotherapy for recurrent spinal cord ependymona.
Chamberlain MC
Cancer; 2002 Sep; 95(5):997-1002. PubMed ID: 12209682
[TBL] [Abstract][Full Text] [Related]
12. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study.
Fowler JM; Blessing JA; Burger RA; Malfetano JH
Gynecol Oncol; 2002 May; 85(2):311-4. PubMed ID: 11972393
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study.
Currie JL; Blessing JA; McGehee R; Soper JT; Berman M
Gynecol Oncol; 1996 Apr; 61(1):94-6. PubMed ID: 8626125
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Walker J; Greer B; Fusco N; McGuire W
Gynecol Oncol; 2002 Apr; 85(1):136-9. PubMed ID: 11925133
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study.
Long HJ; Blessing JA; Sorosky J
Gynecol Oncol; 2005 Nov; 99(2):339-42. PubMed ID: 16051328
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
18. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Rose PG; Markman M; Bell JG; Fusco NL
Gynecol Oncol; 2006 Aug; 102(2):236-9. PubMed ID: 16412499
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
20. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC).
Alici S; Saip P; Eralp Y; Aydiner A; Topuz E
Am J Clin Oncol; 2003 Aug; 26(4):358-62. PubMed ID: 12902885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
